Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Attoub S
,
Arafat K
,
Khalaf T
,
Sulaiman S
,
Iratni R
.
???displayArticle.abstract???
Over recent years, we have demonstrated that Frondoside A, a triterpenoid glycoside isolated from an Atlantic sea cucumber, has potent in vitro and in vivo anti-cancer effects against human pancreatic, breast, and lung cancer. We have also demonstrated that Frondoside A is able to potentiate and/or synergize the anti-cancer effects of major classical cytotoxic agents, namely, gemcitabine, paclitaxel, and cisplatin, in the treatment of pancreatic, breast, and lung cancer, respectively. This study evaluates the impact of Frondoside A alone and in combination with the standard cytotoxic drugs oxaliplatin and 5-fluorouracil (5-FU) in the treatment of colon cancer using three human colon cancer cell lines, namely, HT-29, HCT-116, and HCT8/S11. We demonstrate that Frondoside A, oxaliplatin, and 5-FU cause a concentration- and time-dependent reduction in the number of HT-29 colon cancer cells. A concentration of 2.5 µM of Frondoside A led to almost 100% inhibition of cell numbers at 72 h. A similar effect was only observed with a much higher concentration (100 µM) of oxaliplatin or 5-FU. The reduction in cell numbers by Frondoside A, oxaliplatin, and 5-FU was also confirmed in two other colon cancer cell lines, namely, HCT8/S11 and HCT-116, treated for 48 h. The combinations of low concentrations of these drugs for 48 h in vitro clearly demonstrated that Frondoside A enhances the inhibition of cell numbers induced by oxaliplatin or 5-FU. Similarly, such a combination also efficiently inhibited colony growth in vitro. Interestingly, we found that the inhibition of ERK1/2 phosphorylation was significantly enhanced when Frondoside A was used in combination treatments. Moreover, we show that Frondoside A and 5-FU, when used alone, induce a concentration-dependent induction of apoptosis and that their pro-apoptotic effect is dramatically enhanced when used in combination. We further demonstrate that apoptosis induction upon the treatment of colon cancer cells was at least in part a result of the inhibition of phosphorylation of the survival kinase AKT, leading to caspase-3 activation, poly (ADP-ribose) polymerase (PARP) inactivation, and consequently DNA damage, as suggested by the increase in the level of γH2AX. In light of these findings, we strongly suggest that Frondoside A may have a role in colon cancer therapy when used in combination with the standard cytotoxic drugs oxaliplatin and 5-FU.
Figure 3. Frondoside A enhances the inhibition of coloniesâ growth by (A) oxaliplatin (10 µM), and (B) 5-fluorouracil (10 µM). Data are presented as histograms of the mean percentage of large coloniesâ growth ± S.E.M. (C) The inhibition of ERK phosphorylation by oxaliplatin and 5-fluorouracil was enhanced by Frondoside A in HT-29 colon cancer cells. (D) Densitometry analysis of p-ERK from three different experiments. β-actin was used as an internal loading control of the protein levels, and the normalized p-ERK bandsâ densities are expressed as percentage change in comparison to control samples considered equal to 100%. * Significantly different at p < 0.05. ** Significantly different at p < 0.01. *** Significantly different at p < 0.001. ns (not significant).
Figure 4. Impact of Frondoside A on apoptotic cell death induced by oxaliplatin in HT-29 colon cancer cells. (A,B) Annexin V binding was carried out using Annexin V Dead Cell kit. HT-29 cells were treated with or without Frondoside A (0.5 μM) and indicated concentrations of oxaliplatin (1, 2.5, and 10 μM) individually and in combination for 48 h. Detached and adherent cells were collected and stained with Annexin V and 7-AAD, and then the events for early and late apoptotic cells were counted with the Muse Cell Analyzer as described in Materials and Methods. Data represent the mean ± S.E.M. of at least three independent experiments. Fr represents Frondoside A and Oxa represents oxaliplatin.
Figure 5. Frondoside A enhances apoptotic cell death induced by 5-fluorouracil in HT-29 colon cancer cells. (A,B) Annexin V binding was carried out using Annexin V Dead Cell kit. HT-29 cells were treated with or without Frondoside A (0.5 μM) and indicated concentrations of 5-fluorouracil (0.5, 1, and 10 μM) individually and in combination for 48 h. Detached and adherent cells were collected and stained with Annexin V and 7-AAD, and then the events for early and late apoptotic cells were counted with the Muse Cell Analyzer as described in Materials and Methods. Data represent the mean ± S.E.M. of at least three independent experiments. Fr represents Frondoside A and 5-FU represents 5-fluorouracil.
Figure 6. Western blot analysis of: (A) the effects of Frondoside A, oxaliplatin, 5-fluorouracil, and their combinations on the phosphorylation of the survival kinase AKT and on caspase-3 activation, Poly (ADP-ribose) polymerase (PARP) inactivation and H2AX phosphorylation. HT-29 cells were treated for 24 h with the indicated concentrations of Frondoside A, oxaliplatin, 5-fluorouracil, and their combinations. Densitometry analysis is from three different experiments. β-actin was used as an internal loading control of the protein levels, and the normalized bandsâ densities are expressed as percentage change in comparison to control samples considered equal to 100%. (B) The levels of p-AKT, p-ERK, and p-H2AX after 2 h of treatment with Frondoside A (0.5â2.5 µM).
Al Marzouqi,
Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.
2011, Pubmed,
Echinobase
Al Marzouqi,
Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.
2011,
Pubmed
,
Echinobase
Al Shemaili,
Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer.
2014,
Pubmed
,
Echinobase
Attoub,
Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis.
2013,
Pubmed
,
Echinobase
Dale Rein,
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.
2015,
Pubmed
Dyshlovoy,
The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer.
2016,
Pubmed
Flis,
Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205.
2009,
Pubmed
Janakiram,
Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth.
2010,
Pubmed
,
Echinobase
Jin,
Differential effects of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from sea cucumbers on caspase activation and apoptosis of human leukemia cells.
2009,
Pubmed
,
Echinobase
Li,
Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea cucumber compound, Frondoside A.
2008,
Pubmed
,
Echinobase
Ma,
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.
2012,
Pubmed
,
Echinobase
Matuo,
5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.
2009,
Pubmed
McCubrey,
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
2007,
Pubmed
Moon,
Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells.
2008,
Pubmed
Park,
Frondoside A has an anti-invasive effect by inhibiting TPA-induced MMP-9 activation via NF-κB and AP-1 signaling in human breast cancer cells.
2012,
Pubmed
Raymond,
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
1997,
Pubmed
Sebolt-Leopold,
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.
1999,
Pubmed
Shiragami,
Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.
2013,
Pubmed
Torre,
Global cancer statistics, 2012.
2015,
Pubmed
Weng,
Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKKα-Akt-FKHR signaling cascade.
2013,
Pubmed